Astellas Pharma Inc. Signs Option Deal for DAX-044 Worth Up To $1.34B

What happened

Astellas signed an exclusive option and license deal with Audax for DAX-044, with potential payments up to $1.34B excluding royalties. Audax gets up to $285M in upfront and option payments and will fund development into Phase 1, expected to start in 2027.

Confirmed

Global impact / market context

For Astellas, this spreads the cost of early drug development: Audax pays until Phase 1, limiting near-term spending. Future milestone payments up to $1.34B in total, and royalties, would only follow if the option is exercised and the drug succeeds.

Analyst inference

The deal adds an early immuno-oncology asset to Astellas' pipeline while keeping cash outflows small now. Investors would likely focus on Phase 1 timing and any option decision, since those events determine whether the larger contingent payments become real costs.

Analyst inference

What to watch

1. Phase 1 development for DAX-044 is expected to start in 2027, and Astellas holds a global option to license the treatment after required clearances. Confirmed
2. Watch whether Astellas exercises its option after Phase 1, which would trigger future milestone payments tied to development and commercial success beyond the $285M upfront and option payments. Proposed
3. Track trial progress and data, because failure or delay would likely reduce the chance Astellas pays milestones or royalties, shaping the drug's value to the company. Analyst inference

Evidence

• Original source link unavailable